Shots:
- Fosun Pharma & AriBio have entered into an exclusive global option agreement for the development, registration, manufacturing, & commercialization of AR1001 for AD, expanding their partnership beyond Greater China & 10 ASEAN countries
- AriBio will receive a $60M option fee & retain the right to exercise the option within the agreed period, while Fosun may pay ~$180M in upfront & regulatory milestones upon exercise, with additional sales milestones tied to annual net sales exceeding $2.5B
- AR1001(QD, PO), a phosphodiesterase-5 inhibitor, is being evaluated in the global P-III (POLARIS-AD) trial for early AD, with >1,500 pts enrolled across the US, EU, China, South Korea, & other regions. Topline results are anticipated in 2026
Ref: PRnewswire | Image: Fosun & AriBio | Press Release
Related News: Expedition Therapeutics Enters a ~$645M Licensing Deal with Fosun Pharma for XH-S004
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
